Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Aug 15;24(1):1012.
doi: 10.1186/s12885-024-12763-z.

Peripheral hemoglobin to albumin ratio predicts prognosis in patients with nasopharyngeal carcinoma underwent concurrent chemoradiotherapy

Affiliations

Peripheral hemoglobin to albumin ratio predicts prognosis in patients with nasopharyngeal carcinoma underwent concurrent chemoradiotherapy

Chao Zhang et al. BMC Cancer. .

Abstract

Background: Recently, the hemoglobin to albumin ratio (HAR) has been shown to be closely associated with the survival of certain malignancies. However, its prognostic value in nasopharyngeal carcinoma (NPC) remained to be elucidated. Herein, we aimed to explore the correlation between HAR and overall survival (OS) in NPC patients treated with concurrent chemoradiotherapy (CCRT).

Methods: This retrospective study included a total of 858 patients with NPC receiving CCRT between January 2010 and December 2014 in Sun Yat-sen University Cancer Center. We randomly divided them into the training cohort (N = 602) and the validation cohort (N = 206). We performed univariate and multivariate Cox regression analyses to identify variables associated with OS, based on which, a predictive nomogram was constructed and assessed.

Results: In both the training and validation cohorts, patients were classified into low- and high-HAR groups according to the cutoff value determined by the maximally selected rank statistics. This HAR cutoff value effectively divided patients into two distinct prognostic groups with significant differences. Multivariable Cox analysis revealed that higher T-stage, N-stage, and HAR values were significantly related to poorer prognosis in NPC patients and served as independent prognostic factors for NPC. Based on these, a predictive model was constructed and graphically presented as a nomogram, whose predictive performance is satisfactory with a C-index of 0.744 [95%CI: 0.679-0.809] and superior to traditional TNM staging system [C-index = 0.609, 95%CI: 0.448-0.770].

Conclusion: The HAR value was an independent predictor for NPC patients treated with CCRT, the predictive model based on HAR with superior predictive performance than traditional TNM staging system might improve individualized survival predictions.

Keywords: Concurrent chemoradiotherapy; HAR; Nasopharyngeal carcinoma; Nomogram; Prognosis.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
Kaplan-Meier curves of various survival endpoint between the high-HAR and low-HAR group for overall survival. (A) Training cohort survival curves. (B) Validation cohort survival curves
Fig. 2
Fig. 2
A nomogram to predict the 1-, 3- and 5-year overall survival of NPC patients receiving concurrent chemoradiotherapy
Fig. 3
Fig. 3
The calibration and comparison of the predictive capabilities of this HAR-based prognostic model. (A) Calibration plot in the training cohort. (B) Calibration plot in the validation cohort. (C) Time-dependent ROC curves comparison between the current prognostic model and traditional TNM staging system in the training cohort. (D) Time-dependent ROC curves comparison between the current prognostic model and traditional TNM staging system in the validation cohort

Similar articles

References

    1. Chua MLK, Wee JTS, Hui EP, Chan ATC. Nasopharyngeal carcinoma. Lancet. 2016;387(10022):1012–24. 10.1016/S0140-6736(15)00055-0 - DOI - PubMed
    1. Chen YP, Chan ATC, Le QT, Blanchard P, Sun Y, Ma J. Nasopharyngeal carcinoma. Lancet. 2019;394(10192):64–80. 10.1016/S0140-6736(19)30956-0 - DOI - PubMed
    1. Wong KCW, Hui EP, Lo KW, Lam WKJ, Johnson D, Li L, Tao Q, Chan KCA, To KF, King AD, et al. Nasopharyngeal carcinoma: an evolving paradigm. Nat Rev Clin Oncol. 2021;18(11):679–95. 10.1038/s41571-021-00524-x - DOI - PubMed
    1. Hui EP, Li WF, Ma BB, Lam WKJ, Chan KCA, Mo F, Ai QYH, King AD, Wong CH, Guo R, et al. Integrating postradiotherapy plasma Epstein-Barr virus DNA and TNM stage for risk stratification of nasopharyngeal carcinoma to adjuvant therapy. Ann Oncol. 2020;31(6):769–79. 10.1016/j.annonc.2020.03.289 - DOI - PubMed
    1. Ng WT, Yuen KT, Au KH, Chan OS, Lee AW. Staging of nasopharyngeal carcinoma–the past, the present and the future. Oral Oncol. 2014;50(6):549–54. 10.1016/j.oraloncology.2013.06.003 - DOI - PubMed

MeSH terms

LinkOut - more resources